<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997308</url>
  </required_header>
  <id_info>
    <org_study_id>D1950C00009</org_study_id>
    <secondary_id>EudraCT No.2009-013390-18</secondary_id>
    <nct_id>NCT00997308</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of two
      doses of AZD1446 or placebo in subjects when given for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of AZD1446 dosed for 4 weeks as compared to placebo in healthy elderly male and female volunteers. Safety and tolerability outcomes include adverse events, clinical chemistry and vitals (pulse and blood pressure).</measure>
    <time_frame>During the whole study period, Study days 1-68 (30 days of enrolment , study day 1-28 and follow up visit study days 35-38).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the PK of AZD1446 dosed for 4 weeks in healthy elderly male and female volunteers. PK parameters include renal clearance, AUC (0-24)ss and T1/2 eff.</measure>
    <time_frame>PK sampling taken at defined timepoints during the treatment period (study days 1-28)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD1446 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of AZD1446</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1446 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of AZD1446</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1446</intervention_name>
    <description>Solution, oral, for 4 weeks</description>
    <arm_group_label>AZD1446 Low</arm_group_label>
    <arm_group_label>AZD1446 High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-fertile female, elderly Subjects, aged ≥65 to ≤85

          -  Body mass index (BMI) between 18 and 30 kg/m2

          -  Clinically normal findings on physical examination

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History of severe allergy/hypersensitivity reactions including severe food allergy as
             judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Fransson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca R&amp;DClinical Pharmacology Unit CPUTunavägen 22aS-221 87 LundSweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Björn Paulsson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D SödertäljeSE-151 85 SödertäljeSweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>January 21, 2010</last_update_submitted>
  <last_update_submitted_qc>January 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>AZD1446</keyword>
  <keyword>to investigate safety and tolerability in Healthy subjects during 4 weeks of administration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

